A US judge turned down Novo's request to halt Lilly's Zepbound advertising while the false advertising dispute continues.
Recap by typeshit. Full story at The Pharma Letter.
STAT
The temporary enforcement discretion covers six peptides an FDA advisory committee recommended in July. STAT notes there is little evidence for many of these wellness compounds.
STAT
STAT's Pharmalittle notes Catherine Hanaway says Lilly broke its promise on discounted drugs to hospitals, alongside new results for a Lilly weight loss drug.
STAT notes RFK Jr. and the MAHA movement have embraced peptides, though evidence for many of these wellness compounds is thin. A July FDA panel backed all six.
AP reports agency scientists did not back the administration's effort to loosen rules on peptide drugs that remain unproven.
A guide to employer plans, Medicare Part D's weight-loss exclusion, Medicaid and paying cash, plus how added uses like sleep apnea open coverage.
Saudi sources describe progress on making semaglutide locally, while Novo says only that it is exploring opportunities and gives no timeline.
Loading…